Issue link: https://beckershealthcare.uberflip.com/i/1141789
37 37 CEO/STRATEGY Money no object, but Haven health venture will be long journey, Buffett says By Alia Paavola T here's no guarantee that Haven, the joint health- care venture formed by Berkshire Hathaway, JP Morgan Chase and Amazon last year, will be successful at making healthcare more efficient, Warren Buffet told CNBC in an interview May 6. "It is going to be a long, tough pull to make major changes," Mr. Buffett told CNBC. "It has no guarantee of success at all, but there's nobody I think that's in a better position, in terms of number of employees, ability of the people that are partnering to get along and all kinds of things, to perhaps come up with something to make the system more efficient." The nonprofit health venture set out to tackle rising healthcare costs in the U.S. by improving healthcare for its hundreds of thousands of employees in the U.S. Mr. Buffett said that Haven has taken the first step of what "is bound to be a very long journey." He added that the co-founders, including himself, Jeff Bezos and Jamie Dimon, are willing to spend "whatever money it takes," so long as Haven is making progress. n Highest-paid CEOs in 2018: Who made the list from healthcare By Emily Rappleye T hirty-two healthcare CEOs made e New York Times and Equi- lar's 2018 ranking of highest-paid CEOs in 2018. Of those 32, three executives led some of the nation's largest for-profit hospital systems: King of Prussia, Pa.-based Universal Health Services, Nashville, Tenn.-based HCA Healthcare and Dallas-based Tenet Healthcare. e full list includes 200 chief executives from public companies with revenue of at least $1 billion. Here are the 32 healthcare companies and CEOs that made the list, in order of total compensation in 2018. Total compensation may include salary, bonuses, perks, stock and options. 1. Hologic, Stephen MacMillan — $42 million 2. Align Technology, Joseph Hogan — $42 million 3. Regeneron Pharmaceuticals, Leonard Schleifer — $27 million 4. Centene, Michael Neidorff — $26 million 5. Universal Health Services, Alan Miller — $24 million 6. Abbott Laboratories, Miles White — $23 million 7. CVS Health, Larry Merlo — $22 million 8. Merck, Kenneth Frazier — $21 million 9. Abbvie, Richard Gonzalez — $21 million 10. Johnson & Johnson, Alex Gorsky — $20 million 11. HCA Healthcare, R. Milton Johnson — $20 million 12. Pfizer, Ian Read — $20 million 13. Bristol-Myers Squibb, Giovanni Caforio — $19 million 14. Cigna, David Cordani — $19 million 15. Vertex Pharmaceuticals, Jeffrey Leiden — $19 million 16. ermo Fisher Scientific, Marc Casper — $19 million 17. Amgen, Robert Bradway — $19 million 18. UnitedHealth Group, David Wichmann — $18 million 19. DaVita, Kent iry — $17 million 20. Gilead Sciences, John Milligan — $17 million 21. Alexion Pharmaceuticals, Ludwig Hantson — $16 million 22. Humana, Bruce Broussard — $16 million 23. Celgene, Mark Alles — $16 million 24. Biogen, Michel Vounatsos — $16 million 25. United erapeutics, Martine Rothblatt — $16 million 26. IQVIA Holdings, Ari Bousbib — $16 million 27. Eli Lilly, David Ricks — $16 million 28. Baxter International, José Almeida — $16 million 29. Biomarin Pharmaceutical, Jean-Jacques Bienaimé — $16 million 30. Danaher, omas Joyce Jr. — $15 million 31. Molina Healthcare, Joseph Zubretsky — $15 million 32. Tenet Healthcare, Ron Rittenmeyer — $15 million n Haven's COO is out: 5 things to know By Morgan Haefner T he COO of a health joint venture started by Am- azon, Berkshire Hathaway and JPMorgan Chase stepped down, according to CNBC. Five things to know: 1. Jack Stoddard, a former executive at Comcast and Optum, left nine months into the venture, named Haven. 2. Mr. Stoddard said he left Haven because of the length of his commute from Philadelphia to the com- pany's Boston headquarters, along with other personal reasons. 3. A Haven spokesperson told CNBC: "Jack played an important role in the early stages of Haven, but we un- derstand his decision to leave the company for family reasons. We want to thank him for all of his contributions." 4. Haven has not named a replacement for Mr. Stoddard. 5. Before joining Haven, Mr. Stoddard was part of the executive team that created Optum. n